SCHEMBL16166339

SCHEMBL16166339

O=C1C[C@]2(C(=O)Nc3ccc(Cl)cc32)c2cnn(Cc3ccc(Cl)cc3Cl)c2N1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
IP6K1 Q92551 3/20 0.42
AKR1B1 P15121 1/20 0.38
HTT P42858 2/20 0.36
ALDH1A1 P00352 2/20 0.36
KDM4E B2RXH2 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
COMT P21964 1/20 0.35
LMNA P02545 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
MAPT P10636 1/20 0.35
PDE9A O76083 1/20 0.35
HPGD P15428 1/20 0.34
IDO1 P14902 1/20 0.34
SLC9A1 P19634 1/20 0.33
SIGMAR1 Q99720 1/20 0.33
CXCR3 P49682 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16166482 1.00 IP6K1 (0.42) IP6K1AKR1B1HTTALDH1A1KDM4E
SCHEMBL16166116 0.90 AKR1B1 (0.38) AKR1B1
SCHEMBL16166401 0.89 AKR1B1 (0.40) AKR1B1ALDH1A1IDO1
SCHEMBL16166247 0.89 AKR1B1 (0.40) AKR1B1ALDH1A1IDO1
SCHEMBL16166530 0.87 AKR1B1 (0.36) IP6K1AKR1B1IDO1
SCHEMBL16166349 0.85 AKR1B1 (0.40) IP6K1AKR1B1IDO1
SCHEMBL16175845 0.85 AKR1B1 (0.40) IP6K1AKR1B1IDO1
SCHEMBL16166268 0.85 ADAMTS5 (0.37) AKR1B1KDM4EPDE9A
SCHEMBL16166745 0.83 ELOVL6 (0.37) AKR1B1COMT
SCHEMBL16175826 0.83 NPBWR1 (0.44) AKR1B1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2014167528-A1 SPIROPYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF FOR THE TREATMENT OF VIRAL INFECTIONS NOVARTIS AG (CH) 2014-10-16 WO disclosed
WO-2014167528-A1 SPIROPYRAZOLOPYRIDINE DERIVATIVES AND USES THEREOF FOR THE TREATMENT OF VIRAL INFECTIONS NOVARTIS AG (CH) 2014-10-16 WO disclosed